Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001422848-25-000121
Filing Date
2025-05-13
Accepted
2025-05-13 11:44:14
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5822
  Complete submission text file 0001422848-25-000121.txt   7868
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88797 | Film No.: 25938289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 333 SOUTH HOPE STREET 55TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH HOPE STREET 55TH FLOOR LOS ANGELES CA 90071 213-486-9200
Capital World Investors (Filed by) CIK: 0001422849 (see all company filings)

EIN.: 951411037 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13G/A